A Phase II Study of Pembrolizumab in EGFR Mutant, Tyrosine Kinase Inhibitor Naïve Treatment Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.
- 10 Jun 2017 Biomarkers information updated
- 30 May 2017 Status changed from not yet recruiting to recruiting.